Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by University of Oxford.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
BioMarin Pharmaceutical
Information provided by:
University of Oxford
ClinicalTrials.gov Identifier:
NCT00423280
First received: January 17, 2007
Last updated: August 6, 2008
Last verified: June 2008
  Purpose

The purpose of this study is to determine the effect of 6R-BH4 on vascular function in patients with coronary artery disease. We hypothesize that 6R-BH4 will improve vascular function in these patients.


Condition Intervention Phase
Coronary Artery Disease
Drug: 6R-BH4
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Placebo-Controlled Study of Two Doses of Oral 6R-BH4 on Vascular Function in Subjects With Coronary Artery Disease

Resource links provided by NLM:


Further study details as provided by University of Oxford:

Primary Outcome Measures:
  • Vascular function using non-invasive magnetic resonance imaging (MRI). [ Time Frame: Pre- and post- treatment with 6R-BH4 or placebo ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Laboratory measures of vascular function. [ Time Frame: At time of CABG surgery ] [ Designated as safety issue: No ]

Estimated Enrollment: 66
Study Start Date: November 2006
Estimated Study Completion Date: February 2009
Estimated Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
700mg/day 6R-BH4
Drug: 6R-BH4
6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Other Name: Sapropterin dihydrochloride
Active Comparator: 2
400mg/day 6R-BH4
Drug: 6R-BH4
6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Other Name: Sapropterin dihydrochloride
Placebo Comparator: 3
Placebo
Drug: 6R-BH4
6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Other Name: Sapropterin dihydrochloride

Detailed Description:

Decreased production of nitric oxide (NO) from the endothelium (the layer of cells that forms the lining of all blood vessels) has been shown to contribute to atherosclerosis. NO has multiple beneficial effects on vascular function. Endothelial function can be measured in humans via a number of methods, and endothelial dysfunction has been shown to be a strong adverse predictor of cardiovascular events and mortality.

Tetrahydrobiopterin (BH4) is essential for the production of NO in endothelial cells. 6R-BH4 is a synthetic version of naturally occurring BH4. We aim to investigate the effects of oral 6R-BH4 supplementation on endothelial function in patients with coronary artery disease.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Multi-vessel coronary artery disease scheduled for coronary artery bypass surgery (CABG)

Exclusion Criteria:

  • Inability to provide informed consent
  • Female subject who is pregnant, lactating or planning pregnancy during course of study
  • Prior clinical diagnosis of heart failure requiring diuretic therapy with evidence of severe left ventricular dysfunction
  • Recent acute coronary event (<4 weeks)
  • Emergency CABG
  • Newly diagnosed diabetes mellitus (<1 month)
  • Body weight >130kg
  • Impaired renal function (creatinine >180umol/l)
  • Elevated liver function tests (ALT >50umol/l or AST >2x normal)
  • Pacemakers, ICDs or metallic implants not compatible with MRI scanning
  • Subjects receiving experimental medications or participating in another study
  • Terminally ill subjects
  • Known hypersensitivity to 6R-BH4
  • Concomitant treatment with methotrexate, levodopa, PDE-3 or PDE-5 inhibitors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00423280

Contacts
Contact: Colin Cunnington, MBChB MRCP +44-1865-221866 colin.cunnington@cardiov.ox.ac.uk

Locations
United Kingdom
Department of Cardiovascular Medicine, University of Oxford Recruiting
Oxford, United Kingdom, OX3 9DU
Sponsors and Collaborators
University of Oxford
BioMarin Pharmaceutical
Investigators
Principal Investigator: Keith M Channon, MD FRCP University of Oxford
  More Information

No publications provided by University of Oxford

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Mrs Heather House, University of Oxford
ClinicalTrials.gov Identifier: NCT00423280     History of Changes
Other Study ID Numbers: 06/Q1604/114
Study First Received: January 17, 2007
Last Updated: August 6, 2008
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University of Oxford:
Endothelium
Nitric Oxide
Magnetic Resonance Imaging
Tetrahydrobiopterin

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 21, 2014